1 active not recruiting, 1 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Early Stage: new trials by email Literature Review of Early Stage trials Research Report on Early Stage
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma Sintilimab - Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage | Phase 2 | Completed | Sun Yat-sen University | 55 | 2019-04-28 | 2022-06-09 |
| Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer Enzalutamide, assessment - Breast Cancer, Early Stage | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 50 | 2016-05-19 | 2026-06-24 |
Breast Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Breast Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
Restraint, Physical (1) · Weights and Measures (1) · anlotinib (1) · enzalutamide (1) · sintilimab (1)
Memorial Sloan Kettering Cancer Center (1) · Sun Yat-sen University (1)
China (1) · United States (1)
Tiffany Traina, MD (1) · Zhiming Li (1)